CME Group director Deborah J. Lucas sells $385,425 in stock

Published 18/03/2025, 17:22
CME Group director Deborah J. Lucas sells $385,425 in stock

Deborah J. Lucas, a director at CME Group Inc. (NASDAQ:CME), recently executed a sale of 1,500 shares of the company’s Class A common stock. The transaction took place on March 14, 2025, at a price of $256.95 per share, amounting to a total value of $385,425. The sale occurred as CME’s stock trades near its 52-week high of $264.41, with the shares showing impressive momentum, gaining over 26% in the past six months. Following this sale, Lucas retains ownership of 3,356 shares in the company.

This transaction, filed with the Securities and Exchange Commission, reflects a direct ownership change for Lucas. CME Group, a leading global markets company with a market capitalization of $95.4 billion, continues to be a significant player in the financial services sector. The company has maintained dividend payments for 23 consecutive years, currently offering a 4.1% yield. For deeper insights into insider trading patterns and comprehensive analysis, check out CME’s InvestingPro research report, which includes 10 additional key insights about the company’s performance and outlook.

In other recent news, CME Group has reported significant developments that could impact investors. The company is set to launch a new suite of Bloomberg Commodity Subindex futures, pending regulatory approval, which will cover key sectors like Agriculture, Grains, Livestock, and more. This move is expected to offer market participants new opportunities for risk management and trading strategy enhancement. Additionally, Erste Group has initiated coverage on CME Group with a Buy rating, citing the company’s broad array of risk management tools and potential for earnings surprises as key factors.

Citi analysts have raised their price target for CME Group to $265, reflecting the company’s strong performance and volume growth, particularly in sectors such as agricultural commodities and metals. Meanwhile, Keefe, Bruyette & Woods have adjusted their price target to $257, maintaining a Market Perform rating. This follows CME Group’s quarterly earnings, which surpassed expectations due to stronger revenues and lower effective tax rates.

CME Group’s average daily volume reached a record 33.1 million contracts in February, showing a 12% year-over-year increase, with notable growth in rate contracts and metals. Keefe analysts noted that the company’s first-quarter performance is on a positive trajectory, with potential earnings surpassing consensus estimates if current trends continue. These developments highlight CME Group’s strategic positioning to benefit from current market conditions and volatility.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.